scPharmaceuticals (SCPH)

• Market cap: $150M
• 1 day: -0.66%
• 5 days: -7.12%
• 1 month: -18.48%
• 3 months: -5.96%
• 6 months: -45.36%
• Year to date: -15.97%
• 1 year: -44.85%
• 5 years: -57.14%
• 10 years: -78.72%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Employees: 96

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

687% more call options, than puts

Call options by funds: $614K | Put options by funds: $78K

131% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 16

5.0% more ownership

Funds ownership: 74.49% [Q3] → 79.49% (+5.0%) [Q4]

11% less funds holding

Funds holding: 95 [Q3] → 85 (-10) [Q4]

17% less capital invested

Capital invested by funds: $170M [Q3] → $141M (-$29.1M) [Q4]

35% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 26

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $18 500% upside
• Avg. target: $18 500% upside
• High target: $18 500% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 46 / 180 met price target

500% upside $18

Buy Reiterated

7 Mar 2025